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rHuEPO treatment improves brain and cognitive function of anemic
dialysis patients. Twenty-four patients with chronic renal failure, stabi-
lized on hemodialysis, were treated with recombinant human erythro-
poietin. Before treatment, all patients were anemic (mean Hct =
23.7%). Hematocrits reached normal levels (36.5%) after three months
of treatment. Brain event-related potentials and neuropyschological
tests were used to assess changes in brain and cognitive functions
associated with the correction of anemia. Assessments were done prior
to and after three and twelve months of rHuEPO treatment. The P3
component of the event-related potential increased in amplitude signif-
icantly with treatment, while its latency was unaffected. Of the four
neuropsychological tests administered, scores on two improved signif-
icantly with treatment, and the other two approached significance.
Taken together, these findings suggest that the correction of anemia to
hematocrits near normal in uremic patients by rHuEPO treatment
improves brain and cognitive function by raising levels of sustained
attention, thus increasing speed and efficiency of scanning and percep-
tual-motor functions and enhancing learning and memory. These find-
ings also suggest that anemia, either directly or indirectly, may impair
brain function.
Anemia inevitably accompanies chronic renal failure when
glomerular filtration falls below 30 cc/mm [1]. It is generally
severe (hematocrit 25%) and is present in over 90% of
patients with end-stage renal disease (ESRD) [2]. Although
there are many contributing factors to the anemia, relative
deficiency of the glycoprotein erythropoietin produced in the
kidneys of adults is clearly the proximate cause. The recent
availability of recombinant human erythropoietin has demon-
strated the efficacy and relative safety of this genetically engi-
neered product to completely correct the anemia of chronic
renal failure in most patients [3].
As initially noted by Addison in 1839, uremia is primarily a
neurobehavioral syndrome [4]. This is characterized by
quiet stupor dullness of intellect, sluggishness of
manner, drowsiness Subsequent neuropsychological and
electrophysiological studies have quantitatively documented
the neurobehavioral abnormalities associated with uremic en-
cephalopathy, and the incomplete reversal of these CNS and
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cognitive function abnormalities by chronic hemodialysis
[5—11].
The persistence of at least mild neurobehavioral impair-
ments, despite clinically adequate dialysis therapy, suggests
that factors other than uremic toxins per se might affect the
brain of a uremic patient. Both elevated parathyroid hormone
and aluminum levels have thus been implicated [12, 13]. Since
anemia is almost always present in patients with ESRD and is
severe enough to affect cerebral oxygen delivery [14], we
hypothesized that anemia is a contributor to the neurobehav-
ioral dysfunction of uremia and that correction of anemia with
rHuEPO in anemic stable CHD patients can minimize neuro-
behavioral dysfunction.
Event-related potentials (ERPs) have been shown to be
sensitive, non-invasive and relatively objective indices of cer-
tain aspects of cognitive functioning. In particular, the later
"endogenous" components (such as, N2 and P3; Fig. 1) are so
named because they tend to vary in amplitude and latency as a
function of subject variables such as attention, processing
effort, stimulus evaluation and degree of certainty. In contrast,
earlier components (such as, P1, Nl, and P2; Fig. 1) are termed
"exogenous" because they vary in amplitude and latency as a
function of stimulus parameters such as intensity and repetition
rate. Among the currently identified endogenous components
the P3 has been the most extensively studied [15, 16]. P3
latency has been found to reflect stimulus evaluation time, that
is, the time it takes to identify, categorize and discriminate
stimuli [17—21], and is thus a measure of the rapidity of
information processing. P3 latency increases with task com-
plexity or discriminative difficulty [22—26] and with age [27—32],
presumably reflecting cognitive slowing. In addition, a number
of studies have shown significant latency increases in patients
with dementia of various etiologies [33—39]. Finally, P3 latency
has been found to be prolonged in many dialysis patients [40]. A
previous study from this laboratory [41] found that for renal
patients receiving hemodialysis, the latency of P3 elicited by a
simple discrimination task was significantly greater than that of
controls or patients on peritoneal dialysis.
P3 amplitude, on the other hand, varies with attention, with
the amount of information extracted from a stimulus, and with
certainty or closure [16, 42, 43]. No P3 is elicited by stimuli
which are not attended to or processed in some way. Schizo-
phrenics [44], children with Attention Deficit Disorder [45, 46],
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Fig. 1. Group mean ERPs elicited by target (counted stimuli), before rHuEPO treatment (Pre T, left column), after three months of treatment (T
+ 3 months, middle column), and after 12 months of treatment (T +12 months, right column). Recordings are from midline parietal (Pz) central
(Cz) and frontal (Fz) electrodes. ERP components are labelled on lower left trace. Tick marks on the time line represent 100 msec intervals. Arrows
indicate stimulus onset.
and chronic alcoholics [47] consistently show reduced P3 am-
plitudes as compared to controls. Problems with the regulation
and maintenance of sustained attention are common features of
these conditions. Normal subjects confronted with difficult
discriminations which produce uncertainty as to their decisions
show reductions of P3 amplitude [42, 48], and P3 amplitude is
also reduced when attention must be divided among two tasks
[49].
Neuropsychological tests are designed to test various aspects
of cognitive functioning: attention, perception, learning, mem-
ory, language, motor skills, and executive functions (such as,
organization, planning and mental flexibility) [50]. Many neu-
ropsychological tests provide normative data so that an individ-
ual's performance can be compared with that of a normal group
of the same age and education. Studies of groups of stable CHD
patients have consistently found mild to moderate cognitive
performance abnormalities on measures of memory and learn-
ing, attention and concentration, and speeded perceptual-motor
tasks which require shifting cognitive sets or mental manipula-
tion [5—8, 11].
The aim of this study was to assess the effects of rHuEPO
treatment on the efficiency of cognitive functioning using both
electrophysiological and neuropsychological measures.
Methods
Subjects
The subjects of this study were 24 patients (12 male, 12
female) with ESRD, currently on center hemodialysis (CHD).
Their original disease diagnoses were chronic glomerulonephri-
tis (N = 7), obstructive uropathy (N = 5), diabetic nephropathy
(N = 4), and other/uncertain (N = 8). Their mean age was 46.8
16 years. All were receiving hemodialysis three times weekly
during their participation in this study. The mean duration since
onset of dialysis was 75.7 64 months. All had some degree of
anemia with a group mean hematocrit level of 23.7 4%.
All patients were anephric. Dialysis was performed thrice
weekly using cellophane-based hollow-fiber dialyzers and a
glucose-containing bicarbonate bath. Dialysate potassium and
calcium content varied, depending on individual patient needs.
Dialysis was prescribed to achieve a KT/V (urea) of 1.0 to 1.2
[51] with a PCR of at least 0.8 g/kg/day. This was assessed on a
quarterly basis and the dialysis prescription was adjusted to
keep the KT/V constant over the course of the study.
Electrophysiological assessment
An auditory "oddball" detection task was used for the
collection of electrophysiological data. Subjects listened to
brief (50 msec) 390 Hz, 70 db SPL tone bursts presented
through earphones at a rate of 1 per 1.5 seconds. These tones
were occasionally (20% of trials) and randomly replaced by tone
bursts of higher frequency (460 Hz) and intensity (84 db SPL).
Subjects were instructed to ignore the frequent tones and keep
a silent cumulative count of the rare, target tones. Stimulus
presentation was occasionally interrupted to obtain the sub-
ject's current count of targets. This task continued until 32
artifact-free responses were obtained to target tones and 128 to
frequent tones. Except for the moderate memory load, this
oddball detection task is very simple, since the target and
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frequent tones differ in both intensity and frequency, providing
a double discrimination cue.
Neuropsychological assessment
Four measures were utilized for neuropsychological assess-
ment. The Trail Making Test Part B (TMTB) [521 requires that
the subject connect with lines, in a given sequence, circled
digits and letters randomly distributed on a page. The pre-
scribed sequence is from I to A to 2 to B to 3 to C, etc.
Performance is scored in terms of time to complete the task
correctly. The TMTB assesses attention, visual scanning, psy-
chomotor speed, ability to sequence, and ability to shift cogni-
tive set.
The Symbol Digit Modalities Test (SDMT) [53] requires
matching of printed abstract symbols with a specific digit
according to a key which provides the symbol-number match.
Performance is scored in terms of the number of items correctly
completed in a specified time. The SDMT measures learning,
memory, psychomotor speed and scanning efficiency.
The Controlled Oral Word Association Test (COWAT) [54]
involves the generation of as many words beginning with a
designated letter (such as, F, A, or S) as the subject can within
a specified time period. This task is repeated three times using
different letters. Performance is scored in terms of the total
number of words generated. Verbal fluency, planning and
organization and retrieval from semantic memory are measured
by the COWAT.
For the Rey Auditory-Verbal Learning Test (RAVLT) [55],
the subject learns a list of 15 simple, unrelated words over five
trials. A second list of 15 different words is then given and
thereafter the subject must recall the words from the original
list. For this study, a summary score of total number of words
recalled on trials 1 to 5 was employed. The RAVLT evaluates
verbal learning, immediate memory and retrieval from long-
term storage after interference.
These tests were selected to measure cognitive functions
known to be impaired in renal patients stabilized on dialysis, [5,
7] that is, speeded perceptual-motor tasks requiring flexibility of
thinking and mental manipulation, as well as tests of learning
and memory.
Electrophysiological methods
Subjects were prepared for recording by affixing electrodes in
a midline array at parietal (Pz), central (Cz), and frontal (Fz)
sites. Electrodes on both earlobes served as reference and
ground, respectively. Care was taken to achieve electrode
impedances below 5 kilohms. The subject was then seated in a
sound attenuating recording chamber and fitted with earphones.
The electrodes were connected to amplifiers in the adjoining
room. A computer presented stimuli and averaged the amplified
signals.
The EEG from the three recording electrodes was amplified
(14, 140x), ifitered (0.1 to 50 Hz bandpass), and digitized (250
samples/sec). Digitizing was initiated 100 msec before stimulus
onset (to provide baseline data) and continued for 900 msec
thereafter. Each digitized single-trial ERP epoch was checked
for artifacts by the computer, and any value that exceeded a
preset amplitude criterion due to eyeblink or movement arti-
facts resulted in rejection of that epoch. The computer contin-
ued stimulus presentation until 32 artifact-free target and 128
frequent responses were accumulated. Target and frequent
responses were averaged separately. Averaged responses were
viewed on a CRT monitor to determine whether ERP compo-
nents were clear and measurable. If they were not, the run was
repeated. ERPs from two runs could be summed to increase
signal to noise ratios.
The P3 wave of the ERP, our primary interest, was identified
as the largest positive wave 280 msec or later after stimulus
onset that was present in responses to the target (counted)
stimuli and absent or considerably diminished in responses to
the frequent (non-counted) stimuli. The latency of the P3 peak
was identified as the latency of the maximum positive topo-
graphic field density within the range of a visually identified P3
(that is, the maximum of Pz + Cz + Fz). Thus, a single latency
was measured taking into consideration the recordings at all
three electrode sites. P3 amplitudes for Pz, Cz and Fz were
obtained at this latency. Ni and P2 latencies and amplitudes
were obtained using similar procedures and were measured
from averaged ERPs to both target and frequent tones, since the
exogenous Ni and P2 occur to both stimuli.
ERPs, neuropsychological scores, and hematocrit values
were analyzed using analyses of variance, (repeated measures
ANOVA, BMD P2V), paired t•-tests for contrast measures, and
Pearson correlations. Since preliminary P3 data analysis sug-
gested that total length of time on dialysis might influence P3
change with rHuEPO treatment, that variable was included in
the P3 ANOVAs: a between-subjects (duration) and within-
subjects (treatment by electrode) mixed effects ANOVA (BMD
P2V).
Timing of studies
Subjects were administered all procedures three times: be-
fore rHuEPO treatment (Pre-T), after approximately three
months of treatment (T + 3 mos) when hematocrit values had
stabilized at criterion level (32% or above), and after 12 months
of treatment (T + 12 mos). For each assessment, subjects were
studied on a day following a regularly scheduled and completed
dialysis run as closely as possible to 24 hours after the comple-
tion of the last dialysis, the time when cognitive and electro-
physiological function is best during the dialysis treatment cycle
[56]. Blood for chemical analysis was drawn just prior to the
electrophysiological study, and the neuropsychological assess-
ment was done afterwards.
All 24 subjects completed the first and second electrophysi-
ological assessments, but two of the subjects did not complete
the third (one received a renal transplant and the other was too
ill). Nineteen of the 24 subjects completed the first and second
neuropsychological assessments and 14 completed the third
assessment. The other subjects were lost due to scheduling
difficulties and refusals to participate. Participation required
that subjects come to the center an additional day beyond the
three required for dialysis treatment. This posed problems for
some patients particularly since the lengthy neuropsychological
tests were the last items administered. Some patients were
unwilling or too fatigued to complete the total assessment,
particularly for T + 12. Additional scheduling problems were
created by changes in the personnel administering the neuro-
psychological tests.
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Table 1. Metabolic status of chronic hemodialysis patients before (pre-T) and during (T + 3) months, (T + 12) months treatment with
rHuEPO
Parameter Pre-T
T + 3
Mos
T + 12
Mos
T3-Pre
df t df
Tl2-Pre
t
Na mmol/liter 138.0 138.2 138.8 23 0.30 22 0.92
K mmol/liter 5.3 5.3 5.2 23 0.34 22 —0.02
CO2 mmoi/liter 21.8 20.1 22.8 23 —2.03 22 0.88
BUN mmo!/liter 31.8 33.2 26.0 23 0.82 22
Creatinine pmol/iiter 1113.0 1157.2 1007.0 23 1.50 22 —2.87"
Ca mmol/iiter 2.4 2.5 2.5 23 0.92 21 0.75
P04 mmol/liter
HCT %
1.8
23.7
1.7
36.4
1.9
36.0
23
23
—0.27
16.11"
22
21
1.06
1155b
Albumin g/ liter 43.0 43.0 45.0 23 —0.76 22 2.13a
Total protein g/liter 67.0 65.0 69.0 23 —1.55 22 1.89
PTH pg/mi 2823.5 2550.0 1428.1 13 0.14 15 —1.57
Aluminum jig/liter 29,1 30.9 443.0 15 0.34 15 1.06
Systolic BP 139.5 136.2 141.3 19 —0.51 15 0.19
Diastolic BP 75.6 79.8 80.6 19 1.29 15 1.84
ap< 0.05
b < 0.01
"P < 0.001
Results
Table 1 shows the group mean laboratory and blood pressure
values at the three assessment points. Hematocrit levels
showed a highly significant increase (t = 16.11, P < 0.001) to
normal levels after three months of rHuEPO treatment. Signif-
icant decreases in BUN (t =
—3.74, P < 0.01) and creatinine (t
=
—2.87, P < 0.01) were observed after twelve months of
treatment. Albumin increased (t = 2.13, P < 0.05) at this
assessment point. No other measures showed significant
change.
ERP amplitude
The amplitude of the P3 wave increased significantly with
rHuEPO treatment (F 4.09, P <0.024, Figs. 1, 2 and Table
2). The mean P3 amplitude for the three recording electrodes
(Pz, Cz, Fz) showed the maximum increase with three months
of rHuEPO treatment and no significant change thereafter.
Seventeen of 22 patients (77%) showed P3 amplitude increases
from pre-treatment to 12 months of treatment. As shown in
Figure 3, the amplitude of P3 recorded at the Fz electrode was
significantly smaller than that recorded at central and parietal
leads (electrode effect: F = 7.68, P < 0.0015). While it appears
from Figure 3 that the amplitude increase at Fz with rHuEPO
treatment was greater than that recorded at Pz and Cz, the
treatment by electrode interaction was not significant (F = 1.36,
P < 0.25).
Duration of dialysis did have a significant overall effect on P3
amplitude (duration effect: F = 4.58, P < 0.045, Fig. 4, Table 2),
with those on dialysis less than 50 months having larger P3s
than those on dialysis for more than 50 months at each of the
three testing times. However, the treatment by duration inter-
action did not approach significance (F = 0.37, P < 0.69), that
is, duration of dialysis did not affect the P3 amplitude increase
with rHuEPO treatment.
To determine whether rHuEPO treatment had a selective
effect on the amplitude of the endogenous P3 component or a
more general effect on all components, the amplitudes of the
earlier Ni and P2 exogenous components were measured. As
shown in Figure 2 and Table 2, treatment had a negligible effect
Pre-T I + 3 months T + 12 months
rHuEPO treatment
Fig. 2. Group mean amplitudes of Ni, P2 and P3 before (Pre T) and
during (T + 3 months, T + 12 months) rHuEPO treatment, P3 values
from ERPs to targets are averaged across recording leads (Pz, Cz, Fz).
Ni and P2 values are averaged across recording leads and responses to
both target and non-target stimuli. Ordinate is in microvolts (DV).
Vertical bars represent standard error of the mean. Symbols are: (0)
P3; (Li) P2; (ix) Ni.
on the amplitudes of Ni and P2. The Nl amplitude, averaged
across electrodes and stimuli (frequent and target), showed less
than 0.5 microvolt change with treatment. P2 values also
showed less than 0.5 microvolt change. Treatment effects in the
ANOVAS for Ni and P2 did not approach significance.
ERP latency
rHuEPO treatment had no significant effect on P3 latency
(treatment effect: F = 0.26, P = NS, Table 2). Mean P3 latency
changed less than 10 msec over the three assessment periods.
No main effect of duration or duration by treatment interaction
was found. After three months of treatment, 11 of 24 patients
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Table 2. ERP component amplitude (in microvolts) and latency (in
milliseconds) changes in chronic hemodialysis patients treated with
rHuEPO (N = 22)
Measure Pre-T
T+3
months
T+12
months
P3 amp (Mean; Pz, Cz, 5.72 4.8 7.71 4.6 7.80 4.3k'
Fz)
P3 amp short 7.90 4.2 9.21 4.1 9.77 4.3
(Dialysis <50 mos) a
P3 amp long 4.14 5.5 6.71 5.2 6.35 4.3
(Dialysis >50 mos)
NI amp (Mean; Pz, —3.50 2.4 —3.34 3.3 —3.60 2.1
Cz, Fz)
P2 amp (Mean; Pz, Cz, 3.22 2.5 3.57 3.2 3.42 2.4
Fz)
P3 latency 334 29 332 32 328 32
Ni latency 97 14 96 14 97 10
P2 latency 173 26 176 25 181 29
Data are presented as means SD.
a Main effect of short vs. long: P < 0.05b P < 0.025
(46%) showed a decrease in P3 latency greater than 10 msec
from pre-treatment values, six patients (25%) showed no
change, and seven patients (29%) showed increases. These
percentages were virtually unchanged after 12 months of treat-
ment.
Similarly, the latencies of Ni and P2 were unaffected by
rHuEPO treatment (Table 2). For Ni the mean latencies varied
less than 2 msec over the pre-treatment and two treatment
periods and for P2 less than 10 msec.
Neuropsychological measures
As shown in Table 3, the mean scores from the four neuro-
psychological measures showed improvement with rHuEPO
treatment. After three months of treatment, the SDMT score
increase was significant (t = 2.46, P < 0.025), while those for
RAVLT (t = 1.55, P < 0.075) and COWAT (t = 1.60, P < 0.08)
approached significance. After 12 months of treatment, the
TMTB time to completion, which decreased only slightly at
three months, showed a significant decrease, that is, improve-
ment (t =
—2.85, P < 0.025). The SDMT score showed further
improvement (t = 3.22, P < 0.01), but the RAVLT (t = 1.85, P
<0.09) and COWAT (t = 1.64, P <0.15) scores again failed to
reach significance.
No significant correlations were obtained between any of the
four neuropsychological measures and either P3 amplitude or
P3 latency at the pre-treatment assessment or after three
months of treatment. Correlations obtained for change scores,
that is, three-month rHuEPO treatment values minus pre-
treatment values for the same P3 and neuropsychological vari-
ables, resulted in only one significant relationship. P3 latency
change showed a negative correlation with COWAT change (r
=
—0.57, P < 0.015), indicating that as the number of words
generated increased, P3 latency decreased. Because of the
reduced sample size, correlations with twelve month values
would not be comparable and are not reported.
Hematocrit values correlated significantly with P3 amplitude
at the pre-treatment assessment (r = 0.46, P < 0.02), but
showed no correlation after three months or 12 months of
treatment. Similarly, change scores for Hct and P3 amplitude
were uncorrelated. No significant correlations were obtained
for Hct and P3 latency.
None of the neuropsychological test scores correlated with
Hct values at the pre-treatment assessment. After three months
of rHuEPO treatment, the only correlation obtained was with
TMTB (r =
—0.55, P < 0.015). No correlation was found for
change scores.
In summary, rHuEPO treatment for the correction of anemia
in renal patients stabilized on hemodialysis resulted in signifi-
cant increase in P3 amplitude but no change in P3 latency,
significant improvement on two of four neuropsychological
tests and near significant improvement on two more. These
changes suggest that EPO treatment improved sustained atten-
tion, enhancing performance on complex speeded perceptual-
motor tasks requiring efficient scanning, mental manipulation
and shifting of cognitive sets and, to a lesser extent, learning
and memory.
Discussion
The increase in ERP amplitude produced by rHuEPO treat-
ment was specific to the endogenous P3 component; the exog-
enous N 1 and P2 components were unaffected by treatment.
This selective effect suggests that rHuEPO treatment did not
have the sort of direct physiological effect on brain tissue that
would produce greater neuronal excitability or lowered thresh-
olds and thus increase the amplitude of all ERP components, as
has been observed immediately following hemodialysis [57].
The specific effect on P3 amplitude together with the improve-
ment in neuropsychological test scores points to changes in
higher cognitive functions. However, P3 latency, a measure
shown to be sensitive to such subtle impairments in brain
function as occur early in the course of dementia [58], did not
decrease. This suggests that the improvement in neuropsycho-
logical test performance and the increase in P3 amplitude are
the result of improvement in some aspect of attention [15]. As
indicated at the outset, P3 amplitude is diminished in subjects
who have problems with the maintenance of attention.
The largest increase in P3 amplitude with rHuEPO treatment
was observed in recordings from the scalp electrode placed
over the frontal brain region. While it cannot be assumed that a
scalp electrode reflects only, or even primarily, brain activity in
the region immediately underlying that electrode, and it is
thought that the neural generators of the P3 wave are widely
distributed throughout the brain [59—fill, it is nonetheless an
interesting observation since the frontal lobes have an impor-
tant role in the regulation of attention [62].
The fact that hematocrit values were significantly correlated
with P3 amplitude before but not after EPO treatment provides
additional support for the view that severe anemia may be a
factor in the cognitive impairments noted in uremic patients.
That is, before treatment the degree to which a patient is anemic
is related to diminished P3 amplitude, but once Hct is normal-
ized, any relation with Hct disappears. Similar findings have
recently been reported by Grimm et al [63].
The lack of change in P3 latency with rHuEPO treatment was
contrary to expectation, since P3 latency has been shown to be
abnormally prolonged in many CHD patients [40]. Moreover,
significant decrease in P3 latency with rHuEPO treatment was
also a major finding in the recent report by Grimm et al [63],
which utilized measures (oddball, TMT) very similar to ours on
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Fig. 3. Group mean P3 amplitudes before
(Pre T) and during (T + 3 months, T + 12
months) rHuEPO treatment. P3 values are
_________________________________________________ from the three midline recording electrodes
placed as shown on the head to the right.
Ordinate and vertical markers as in Figure 2.
Symbols are: (0) Pz; (U) Cz; () Fz.
discrepancy in latency findings, it should be noted that Grimm
{ et a! [63] found near significant (P < 0.06) P3 amplitude
L
increases with rHuEPO treatment.
The pre-rHuEPO treatment scores on the neuropsychological
measures were quite similar to the scores reported on these
tests in previously studied groups of stable CHD patients [5—8,
11]. Current, age-adjusted norms [53, 64—66] indicate that the
mean pretreatment scores fall at the seventh percentile (border-
line range) for SDMT, the 16th percentile (low average) for
RAVLT, the 46th percentile (average) for COWAT and the 14th
percentile (low average) for TMTB. After 12 months of treat-
ment, mean scores for all tests were within the average range:
SDMT 30th percentile, RAVLT 51st percentile, COWAT 74th
percentile, TMTB 32nd percentile. A number of inferences can
be drawn from these comparisons with normative data. First,
pre-treatment scores were at most only mildly impaired, a
finding consistent with other reports that stable CHD patients
T + 12 months manifest either normal functioning or mild to moderate impair-
ment in selected areas of cognitive function [5—8, 11]. Second,
after 12 months of treatment all scores were well within the
normal range. Third, those measures on which performance
was most impaired before treatment (SDMT, TMTB) showed
the greatest improvement with treatment. It is of interest that
both tests share the requirement for frequent and rapid shifts in
attention.
Both the SDMT and TMTB, the tests on which performance
improved significantly with rHuEPO treatment, have been
shown to be relatively insensitive to test-retest effects and
stable over time [53, 67]. Thus, it is unlikely that the improve-
ment can be attributed to practice effects.
The results of this study suggest some difference in the timing
of ERP and neuropsychological test performance changes with
rHuEPO treatment. P3 amplitude increased significantly alter
three months of treatment and showed no significant change
thereafter (Table 2). This paralleled the course of hematocrit
changes. SDMT also showed significant improvement after
three months, and additional improvement at 12 months (Table
3). In contrast, TMTB time to completion showed only slight
improvement after three months of treatment but significant
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'ig. 4. Group mean P3 amplitudes (average of Pz, Cz, Fz recordings)
ror patients on dialysis for long (>50 months) and short (<50 months)
,eriods. Symbols are: (0) short; (EJ) long.
s patient group comparable in age (51.5 years). While the basis
or this discrepancy in findings is not yet clear, the P3 latency
iata suggest that the patients in the Grimm et al [63] study may
ave been more ill and perhaps more cognitively impaired than
:hose we studied. Prior to treatment their patients had a mean
P3 latency of 391 msec as compared to 332 msec for our
atients, a difference of approximately 60 msec. Given the
;imilarity in paradigms, it would be expected that P3 latency for
lormal subjects on both tasks would be approximately 330 28
nsec [28]. Thus, patients in the Grimm et al [63] study had P3
atencies more than 2 standard deviations beyond the expected
lormal mean, while patients in our study had normal latencies.
Elence, it is possible that we did not observe consistent P3
atency changes because the majority of patients in our study
lad normal P3 latencies before rHuEPO treatment. Despite the
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Table 3. Neuropsychological test score changes in chronic hemodialysis patients treated with rHuEPO
Variable N Pre-T N T + 3 Mos N
T+12
Mos
T+
df
3mosvs.
Pre
t
T+
df
12M
Pre
osvs.
t
SDMT
RAVLT
COWAT
TMTB
17
18
18
18 1
39.3 11.5
43.2 14.7
40.5 15.6
14.4 57.5
18
19
19
18
45.5 11.4
49.7 11.3
45.5 13.2
112.6 63.9
15
15
15
15
47.0 12.0
51.0 10.6
49.5 15.3
92.5 51.1
16
17
17
17
2.46a
1.55
1.60
—0.12
13
13
13
13
322b
1.85
1.64
Data are presented as means SD.
ap <0.025
b P < 0.01
improvement at T + 12 months. Given our limited knowledge of
the effects of anemia and its correction on brain and cognitive
functions, we can only speculate concerning factors accounting
for the difference in rate of change for electrophysiological and
neuropsychological measures. One obvious possibility con-
cerns level of task demand and complexity. Both SDMT and
TMTB are complex tasks requiring sustained attention, rapid
accurate scanning, psychomotor speed and memory. Compared
to these measures, the oddball task used to elicit ERPs is much
simpler and less demanding. It is conceivable that the effects of
the correction of anemia may be immediately apparent in the
less demanding cognitive functions subserving simple tasks but
the more complex cognitive functions involved in demanding
tasks may take longer to normalize. Moreover, ERPs appear to
be less sensitive to such factors as mood or emotional state than
is neuropsychological test performance.
Though brain dysfunction has been known to occur in uremic
patients for over 150 years, a comprehensive understanding of
its pathogenesis is lacking. Initially, attention was focused on
alterations in brain structure in uremia. The seminal study of
Olsen [68], while revealing multiple areas of neuronal degener-
ation in the brains of uremics who had died, failed to succeed in
correlating these findings with the premorbid clinical signs and
symptoms.
Many abnormalities of brain metabolism have also been
described in the presence of uremia. These include decreased
utilization of ATP [69], lowered oxygen and energy con sump-
tion [70], decreased Na-K-ATPase activity [71], increased brain
calcium content [72], altered brain cell permeability [73] and
elevated CSF tryptophan [74]. Some of these abnormalities may
be directly or indirectly caused by retained endogenous uremic
toxins. Others might be related to hormonal abnormalities seen
in uremia (such as hyperparathyroidism) or exogenous toxins
(such as aluminum).
The results of the present study suggest that anemia can also
affect brain function in uremic patients. There are at least two
possible mechanisms for this effect that deserve further study.
First, it has been shown that cerebral blood flow is increased
above normal in uremics [75]; this increase can be attributed to
anemia. The high cerebral blood flow in the presence of anemia
and uremia would result in a high delivery of uremic toxins to
the brain. By treating the anemia and thus lowering cerebral
blood flow, toxin delivery to the brain may be decreased and an
improvement in CNS function would be expected, as we have
seen. In this model, correction of anemia indirectly improves
"brain uremia." If this mechanism is operative, it would be
important to anemic uremics, but not generalizable to other
anemic patients.
Although the prescribed dose of dialysis was kept constant in
this study, both BUN and creatinine levels fell significantly
after twelve months of rHuEPO treatment. There was no
change in PCR (1.21 — 1.20 glkg!day) or dry weight (60.3 kg —
59.1 kg) suggesting maintenance of a stable muscle mass and
state of nutrition. Though the change in BUN and creatinine
may have further contributed to the amelioration of "brain
uremia" described above, it does not account for the improve-
ment in ERP and neuropsychological measures observed after
three months of treatment.
Secondly, the effect of correction of anemia in uremics might
reflect a beneficial effect for patients with anemia of other
causes. This would be the case if the effect seen was caused by
the improved cerebral oxygen delivery associated with correc-
tion of anemia. Optimal brain oxygen delivery occurs at an
hematocrit of —33% [14]. At levels below this oxygen delivery
falls precipitously. The decreased oxygen delivery might impair
a variety of brain metabolic functions as reflected in the
electrophysiological and cognitive function tests reported in
this study.
Either or both of these mechanisms could have produced the
attenuated P3 amplitudes observed in patients on dialysis for
more than 50 months.
Though abnormalities of cerebral function have not been
reported in anemic patients without uremia, systematic studies
in this group of patients have not been conducted. Such studies
would be important to help further our understanding of brain
metabolism, its dependence on oxygen delivery, and the poten-
tial harmful effects of prolonged anemia on the brain.
Including this report, three recent studies have assessed the
effects of rHuEPO treatment in renal patients stabilized on
hemodialysis. All indicate that the correction of anemia im-
proves aspects of brain/cognitive function. DiPaolo et al [76]
and Grimm et al [63] report shortened latencies or increased
amplitudes of EPs from somatosensory, auditory and visual
pathways suggestive of more efficient functioning at the brain-
stem level. Both the Grimm et al study and ours find changes
indicative of improvement in cognitive functioning in electro-
physiological (P3) and neuropsychological measures. While the
specific measures which show improvement vary across stud-
ies, results at this early stage of investigation point to significant
improvement in brain and cognitive function with the correction
of anemia by rHuEPO treatment.
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